Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1, Randomized, Double-Blind, Placebo-Controlled Study, to Evaluate the Safety, Tolerability and Pharmacokinetics of Single and Multiple Ascending Doses (SAD-MAD) of ALZ002 DS in Healthy Volunteers

Next Previous
Search
Trial Profile

A Phase 1, Randomized, Double-Blind, Placebo-Controlled Study, to Evaluate the Safety, Tolerability and Pharmacokinetics of Single and Multiple Ascending Doses (SAD-MAD) of ALZ002 DS in Healthy Volunteers

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 31 Jul 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs ALZ-002 (Primary)
  • Indications Huntington's disease; Machado-Joseph Disease; Spinocerebellar ataxias; X-linked bulbo-spinal atrophy
  • Focus Adverse reactions; First in man
  • Sponsors Allianz Pharmascience; AnnJi Pharmaceutical

    • Most Recent Events

    • 27 Jul 2023 According to a Avenue Therapeutics media release, this trial demonstrate the drug's excellent safety profile in healthy volunteers.
    • 16 Aug 2021 Status changed from recruiting to completed.
    • 11 Jan 2021 Planned End Date changed from 31 Jan 2021 to 31 Aug 2021.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top